SG10201912961QA - Compositions and Methods for Treating Retinal Diseases - Google Patents

Compositions and Methods for Treating Retinal Diseases

Info

Publication number
SG10201912961QA
SG10201912961QA SG10201912961QA SG10201912961QA SG10201912961QA SG 10201912961Q A SG10201912961Q A SG 10201912961QA SG 10201912961Q A SG10201912961Q A SG 10201912961QA SG 10201912961Q A SG10201912961Q A SG 10201912961QA SG 10201912961Q A SG10201912961Q A SG 10201912961QA
Authority
SG
Singapore
Prior art keywords
compositions
methods
retinal diseases
treating retinal
treating
Prior art date
Application number
SG10201912961QA
Inventor
Henry Klassen
Jing Yang
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47177629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201912961Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Publication of SG10201912961QA publication Critical patent/SG10201912961QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin
SG10201912961QA 2011-05-18 2012-05-17 Compositions and Methods for Treating Retinal Diseases SG10201912961QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161487419P 2011-05-18 2011-05-18

Publications (1)

Publication Number Publication Date
SG10201912961QA true SG10201912961QA (en) 2020-03-30

Family

ID=47177629

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201912961QA SG10201912961QA (en) 2011-05-18 2012-05-17 Compositions and Methods for Treating Retinal Diseases
SG2013082680A SG194843A1 (en) 2011-05-18 2012-05-17 Compositions and methods for treating retinal diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2013082680A SG194843A1 (en) 2011-05-18 2012-05-17 Compositions and methods for treating retinal diseases

Country Status (14)

Country Link
US (8) US9107897B2 (en)
EP (3) EP3824910A1 (en)
JP (8) JP6223963B2 (en)
KR (1) KR101972610B1 (en)
CN (3) CN103687626B (en)
AU (1) AU2012255735B2 (en)
BR (1) BR112013029663A2 (en)
CA (1) CA2835215C (en)
EA (1) EA026193B1 (en)
HK (1) HK1221739A1 (en)
IL (2) IL229257B (en)
MX (1) MX350951B (en)
SG (2) SG10201912961QA (en)
WO (1) WO2012158910A2 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824910A1 (en) 2011-05-18 2021-05-26 The Regents of The University of California Compositions and methods for treating retinal diseases
US8563304B2 (en) 2011-06-14 2013-10-22 The Schepens Eye Research Institute Low oxygen culture conditions for maintaining retinal progenitor cell multipotency
CN108588025A (en) * 2012-02-17 2018-09-28 斯格本斯眼科研究所 The phenotypic spectrum of human retina progenitor cells
US10980865B2 (en) * 2012-08-10 2021-04-20 Aquavit Pharmaceuticals, Inc. Direct application system and method for the delivery of bioactive compositions and formulations
PT2970903T (en) 2013-03-15 2024-02-26 Astellas Inst For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US11241460B2 (en) 2013-03-15 2022-02-08 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
CN105814192A (en) * 2013-10-09 2016-07-27 加利福尼亚大学董事会 Methods of mammalian retinal stem cell production and applications
US10930373B2 (en) * 2014-03-24 2021-02-23 Life Technologies Corporation Methods and systems for knowledge discovery using biological data
WO2016021894A1 (en) * 2014-08-04 2016-02-11 영남대학교 산학협력단 Pharmaceutical composition for preventing or treating cellular senescence or senescence-associated diseases, containing cd9 antibody as active ingredient
EA201791416A1 (en) 2014-12-30 2017-11-30 Селл Кьюр Нейросайансес Лтд. POPULATION OF RPE CELLS AND METHODS TO OBTAIN THEM
CN106318909B (en) * 2015-06-23 2019-04-05 何伟 A kind of retinal progenitor cells and its preparation with treatment Retinal degeneration function
WO2017026694A1 (en) * 2015-08-11 2017-02-16 영남대학교 산학협력단 Pharmaceutical composition for preventing or treating ocular diseases, containing cd9 antibody as active ingredient
EP4092109A1 (en) * 2015-09-08 2022-11-23 Sumitomo Pharma Co., Ltd. Method for producing retinal pigment epithelial cells
US10891729B2 (en) * 2015-11-18 2021-01-12 University Of Louisville Research Foundation, Inc. Automated methods for the objective quantification of retinal characteristics by retinal region and diagnosis of retinal pathology
US11679180B2 (en) * 2016-12-07 2023-06-20 Mayo Foundation For Medical Education And Research Methods and materials for using fibrin supports for retinal pigment epithelium transplantation
EP3332695B1 (en) * 2016-12-09 2021-05-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Measurement device
CN106822182A (en) * 2016-12-27 2017-06-13 广州姿生生物科技有限公司 A kind of cell extract and application thereof
CA3088957A1 (en) * 2017-01-17 2018-07-26 Tufts Medical Center, Inc. Adoptive transfer of plasmacytoid dendritic cells to prevent or treat ocular diseases and conditions
US11753623B2 (en) 2017-06-05 2023-09-12 The Regents Of The University Of California Compositions for treating retinal diseases and methods for making and using them
CN117379543A (en) * 2017-08-20 2024-01-12 加州大学董事会 Modulation of Wnt5a for treatment of glaucoma
US20220175844A1 (en) * 2018-02-02 2022-06-09 University Of Maryland, Baltimore Methods of treating optic nerve diseases using neural progenitor cell growth factors
CA3092966A1 (en) * 2018-03-02 2019-09-06 The Schepens Eye Research Institute System and method for treating meibomian gland dysfunction
CN108507989B (en) * 2018-03-28 2021-10-26 韶关学院 Quantum dot immunochromatography detection card and detection method for detecting oxaprozin by double-antibody sandwich immune competition method
WO2019243462A1 (en) * 2018-06-20 2019-12-26 Biolamina Ab Methods and compositions for producing retinal pigment epithelium cells
CN110755427A (en) * 2018-07-28 2020-02-07 华中科技大学 Medicine for treating retinal degenerative disease
RU2707264C1 (en) * 2018-09-26 2019-11-25 ФГБНУ "НИИ глазных болезней" Method of stem cell transplantation in retinal pigment epithelium in experiment
US20210208130A1 (en) 2018-09-27 2021-07-08 The Regents Of The University Of California Assays for cell-based therapies or treatments
CA3113675A1 (en) * 2018-09-27 2020-04-02 The Regents Of The University Of California Methods of human retinal progenitor cell isolation and culture
CN109136187A (en) * 2018-09-29 2019-01-04 浙江省人民医院 A kind of method of crinial bone mesenchyma stem cell differentiation induction nerve cell
WO2020142349A1 (en) * 2019-01-04 2020-07-09 The Regents Of The University Of California Compositions and methods for promoting angiogenesis in the eye
WO2020223226A1 (en) * 2019-04-28 2020-11-05 Nasonkin Igor Compositions and methods for the treatment of retinal degeneration
CN110527698B (en) * 2019-08-23 2021-10-01 温氏食品集团股份有限公司 Method for improving genome site-specific insertion efficiency by using small molecular compound
CN110548143A (en) * 2019-09-17 2019-12-10 武汉大学 Application of cannabinoid receptor CB1 in retinal photoreceptor cell degenerative diseases
AU2020383622A1 (en) * 2019-11-15 2022-06-16 Secretome Therapeutics, Inc. Immortalized cardiac stem cells for cardiac repair
CN112807275B (en) * 2019-11-15 2022-05-20 湖北远大天天明制药有限公司 Ophthalmic composition and preparation method and application thereof
CN111793683B (en) * 2020-08-06 2021-04-27 复旦大学附属眼耳鼻喉科医院 Biomarker for detecting diabetic retinopathy, detection kit and application
CN111926074B (en) * 2020-09-03 2021-04-23 南京医科大学眼科医院 Biomarker for detecting ischemic retinopathy, detection kit and application
CN114917367A (en) * 2021-06-02 2022-08-19 中国科学院动物研究所 Application of LHX2 in promoting injury repair and regeneration of central system neurons
WO2023278382A1 (en) 2021-06-29 2023-01-05 Staffan Holmin Endoluminal delivery cannula
CN113444789A (en) * 2021-08-27 2021-09-28 中国医学科学院北京协和医院 Glaucoma-associated biomarkers and uses thereof
WO2023211857A1 (en) 2022-04-25 2023-11-02 Lineage Cell Therapeutics, Inc. Methods and compositions for treating vision loss
WO2023215602A1 (en) * 2022-05-06 2023-11-09 The Schepens Eye Research Institute, Inc. Isolation, enrichment, and expansion of human rod progenitor cells and extracellular vesicles derived therefrom
CN115216445B (en) * 2022-08-04 2023-11-14 辽宁何氏医学院 Culture medium and application thereof in culturing retina progenitor cells
WO2024044134A1 (en) * 2022-08-23 2024-02-29 Astellas Institute For Regenerative Medicine Photoreceptor rescue cell (prc) compositions and methods for treatment of ocular disorders

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4868121A (en) 1985-02-07 1989-09-19 Mcdonnell Douglas Corporation Islet isolation process
US5079160A (en) 1987-06-08 1992-01-07 Lacy Paul E Method to isolate clusters of cell subtypes from organs
US5270192A (en) 1991-02-07 1993-12-14 Monsanto Company Biological artificial liver
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US6045791A (en) 1992-03-06 2000-04-04 Photogenesis, Inc. Retinal pigment epithelium transplantation
US5422261A (en) 1993-04-16 1995-06-06 Baxter International Inc. Composition containing collagenase and chymopapain for hydrolyzing connective tissue to isolate cells
US5466233A (en) 1994-04-25 1995-11-14 Escalon Ophthalmics, Inc. Tack for intraocular drug delivery and method for inserting and removing same
US7361332B2 (en) 1995-03-17 2008-04-22 The Regents Of The University Of California Treating tumors using implants comprising combinations of allogeneic cells
US6933331B2 (en) 1998-05-22 2005-08-23 Nanoproducts Corporation Nanotechnology for drug delivery, contrast agents and biomedical implants
CA2216439A1 (en) 1996-09-25 1998-03-25 Derek Van Der Kooy Pharmaceuticals containing retinal stem cells
BR9809284A (en) * 1997-04-21 2004-08-03 Univ Florida Construct and process for high-level polynucleotide expression
US6289377B1 (en) 1997-11-10 2001-09-11 General Instrument Corporation Dynamic network configuration of a one-way adapter using a proxy agent that communicates with a resource server through a configured return path adapter
US6886568B2 (en) 1998-04-08 2005-05-03 The Johns Hopkins University Method for fabricating cell-containing implants
US6184035B1 (en) 1998-11-18 2001-02-06 California Institute Of Technology Methods for isolation and activation of, and control of differentiation from, skeletal muscle stem or progenitor cells
NZ513303A (en) * 1999-02-04 2003-03-28 Technion Res & Dev Foundation Three dimensional plug flow bioreactor, and its use for the maintenance and expansion of hemopoietic stem cells and/or progenitor cells
US7105150B2 (en) 1999-02-12 2006-09-12 Stemcells California, Inc. In vivo screening methods using enriched neural stem cells
US6777231B1 (en) 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
BR0014864A (en) * 1999-10-15 2002-11-19 Advanced Cell Tech Inc Methods of producing differentiated progenitor cells and defective embryonic stem cells in lineage
DE60142553D1 (en) * 2000-02-11 2010-08-26 Children S Hospital Of Orange INSULATION AND TRANSPLANTATION OF RETINAL STEM CELLS
AU2002305053A1 (en) 2001-03-26 2002-10-08 University Of Washington Method of inducing proliferation of retinal stem cells
AU2002303437A1 (en) 2001-04-20 2002-11-05 Children's Hospital Of Orange County Isolation of neural stem cells using gangliosides and other surface markers
WO2002088332A1 (en) 2001-04-24 2002-11-07 Hokkaido Technology Licensing Office Co.,Ltd. Small liver cell-rich colony, method of preparing the same, method of maturing the same into liver tissue and method of estimating drug function using the matured small liver cell-rich colony
EP1404297B1 (en) 2001-06-12 2011-04-27 The Johns Hopkins University School Of Medicine Reservoir device for intraocular drug delivery
US7166133B2 (en) 2002-06-13 2007-01-23 Kensey Nash Corporation Devices and methods for treating defects in the tissue of a living being
CN1219053C (en) 2002-08-19 2005-09-14 上海第二医科大学附属第九人民医院 Allogenic tissue engineered cartilage and its application
WO2004020597A2 (en) 2002-08-27 2004-03-11 Stemcells, Inc. Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
CN1506042A (en) 2002-12-11 2004-06-23 苏加璐 Method and composition for improving skin state using compound from fetal cell and tissue
CN100349621C (en) 2002-12-18 2007-11-21 上海第二医科大学附属第九人民医院 Method for inducing bone marrow substrate stem cell into cartilage
US7241455B2 (en) 2003-04-08 2007-07-10 Boston Scientific Scimed, Inc. Implantable or insertable medical devices containing radiation-crosslinked polymer for controlled delivery of a therapeutic agent
EP1648298A4 (en) 2003-07-25 2010-01-13 Dexcom Inc Oxygen enhancing membrane systems for implantable devices
US20050048021A1 (en) 2003-08-27 2005-03-03 Robert Salem Proportional method for diagnosing and appropriately cleansing and conditioning hair and a kit of proportional shampoos and conditioners for practicing the method
JP2007505932A (en) 2003-09-18 2007-03-15 マクサイト， インコーポレイテッド Transscleral delivery
US7794706B2 (en) 2003-10-14 2010-09-14 Medivas, Llc Bioactive wound dressings and implantable devices and methods of use
EP4248752A3 (en) 2004-01-23 2024-01-03 President And Fellows Of Harvard College Improved modalities for the treatment of degenerative diseases of the retina
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
EP1796693A2 (en) 2004-08-26 2007-06-20 Chandrashekhar P. Pathak Implantable tissue compositions and method
US7351423B2 (en) 2004-09-01 2008-04-01 Depuy Spine, Inc. Musculo-skeletal implant having a bioactive gradient
NZ561148A (en) * 2004-12-08 2008-12-24 Sirion Therapeutics Inc Methods, assays and compositions for treating retinol-related diseases
US7759120B2 (en) 2005-03-02 2010-07-20 Kps Bay Medical, Inc. Seeding implantable medical devices with cells
US7541186B2 (en) 2006-02-22 2009-06-02 University Of Washington Method of generating human retinal progenitors from embryonic stem cells
US8197435B2 (en) 2006-05-02 2012-06-12 Emory University Methods and devices for drug delivery to ocular tissue using microneedle
WO2007130060A2 (en) 2006-05-03 2007-11-15 Schepens Eye Research Isolation and therapeutic application of adult retinal stem cells collected from extra-retinal tissues
US9061017B2 (en) * 2006-05-03 2015-06-23 The Schepens Eye Research Institute, Inc. Isolation and therapeutic application of adult retinal stem cells collected from extra-retinal tissues
US20080119909A1 (en) 2006-11-21 2008-05-22 Neurotrophincell Pty Limited Cell implantation to prevent and/or treat hearing loss
PL2209888T3 (en) 2007-10-12 2020-05-18 Astellas Institute For Regenerative Medicine Improved methods of producing rpe cells and compositions of rpe cells
US8481313B2 (en) 2008-04-22 2013-07-09 Regenerative Research Foundation Retinal pigment epithelial stem cells
US8425473B2 (en) 2009-01-23 2013-04-23 Iscience Interventional Corporation Subretinal access device
WO2010093873A2 (en) 2009-02-12 2010-08-19 Incept, Llc Drug delivery through hydrogel plugs
US9359592B2 (en) * 2009-10-06 2016-06-07 Snu R&Db Foundation Method for differentiation into retinal cells from stem cells
DE102009052552A1 (en) 2009-11-10 2011-05-26 Fluoron Gmbh syringe
EP3824910A1 (en) 2011-05-18 2021-05-26 The Regents of The University of California Compositions and methods for treating retinal diseases
US8563304B2 (en) 2011-06-14 2013-10-22 The Schepens Eye Research Institute Low oxygen culture conditions for maintaining retinal progenitor cell multipotency

Also Published As

Publication number Publication date
US10781422B1 (en) 2020-09-22
CN111265551A (en) 2020-06-12
KR101972610B1 (en) 2019-04-25
IL229257A0 (en) 2014-01-30
JP7232524B2 (en) 2023-03-03
EA201301277A1 (en) 2014-04-30
JP2020054363A (en) 2020-04-09
US20160319243A1 (en) 2016-11-03
EP2709672B1 (en) 2019-12-18
EP2709672A4 (en) 2014-12-31
JP6223963B2 (en) 2017-11-01
WO2012158910A3 (en) 2013-02-28
US20190085287A1 (en) 2019-03-21
EP2709672A2 (en) 2014-03-26
EP3824910A1 (en) 2021-05-26
US10041041B2 (en) 2018-08-07
CA2835215C (en) 2023-10-10
US20210189333A1 (en) 2021-06-24
IL229257B (en) 2018-08-30
US20140186309A1 (en) 2014-07-03
JP2023030176A (en) 2023-03-07
US9963675B2 (en) 2018-05-08
AU2012255735A1 (en) 2013-11-28
IL260585B (en) 2019-08-29
JP2023030175A (en) 2023-03-07
US20200325444A1 (en) 2020-10-15
JP2017035108A (en) 2017-02-16
CN105349492B (en) 2019-04-16
BR112013029663A2 (en) 2020-07-21
SG194843A1 (en) 2013-12-30
US9107897B2 (en) 2015-08-18
US20240026290A1 (en) 2024-01-25
JP2018186832A (en) 2018-11-29
US10752882B2 (en) 2020-08-25
JP6571252B2 (en) 2019-09-04
CN103687626B (en) 2020-06-30
EA026193B1 (en) 2017-03-31
CN105349492A (en) 2016-02-24
KR20140033431A (en) 2014-03-18
EP3636286A1 (en) 2020-04-15
CN103687626A (en) 2014-03-26
JP6931340B2 (en) 2021-09-01
US10822585B2 (en) 2020-11-03
CA2835215A1 (en) 2012-11-22
JP2021164464A (en) 2021-10-14
HK1221739A1 (en) 2017-06-09
WO2012158910A2 (en) 2012-11-22
MX350951B (en) 2017-09-26
AU2012255735B2 (en) 2017-05-25
US20150328262A1 (en) 2015-11-19
US20200157498A1 (en) 2020-05-21
US11739294B2 (en) 2023-08-29
MX2013013434A (en) 2014-09-04
JP2014515261A (en) 2014-06-30
JP2018188469A (en) 2018-11-29

Similar Documents

Publication Publication Date Title
IL260585B (en) Compositions and methods for treating retinal diseases
IL274469A (en) Compositions, uses and methods for treatment of metabolic disorders and diseases
EP2684167A4 (en) Compositions and methods useful for treating diseases
HK1202416A1 (en) Compositions and methods for preventing and treating oral diseases
HK1201475A1 (en) Methods and compositions for treating pain
HK1210968A1 (en) Compositions and treatment for eye diseases and disorders
ZA201305783B (en) Composition and methods for treating cardiovascular diseases
EP2701742A4 (en) Compositions and method for treating autoimmune diseases
EP2655334A4 (en) Compositions and methods useful for treating diseases
EP2771030A4 (en) Compositions and methods for treatment of proteinopathies
EP2691529A4 (en) Methods and compositions for treating brain diseases
DK3292875T3 (en) Compositions and methods for treating diseases
ZA201309557B (en) Methods of treatment for retinal diseases
EP2558104A4 (en) Method and ophthalmic composition for treating retinal disease
EP2709632A4 (en) Compositions and methods for the treatment of skin diseases
EP2670243A4 (en) Compositions and methods for treatment of glaucoma
SG11201402899TA (en) Methods and compositions for treating viral diseases
WO2013003465A9 (en) Methods and compositions for treating skin
EP2714082A4 (en) Compositions and methods for treating pain
HK1199617A1 (en) Compositions and methods for treating viral diseases